Bortezomib

Generic Name
Bortezomib
Brand Names
Velcade, Bortezomib Accord, Bortezomib Hospira, Bortezomib Fresenius Kabi, Bortezomib Sun
Drug Type
Small Molecule
Chemical Formula
C19H25BN4O4
CAS Number
179324-69-7
Unique Ingredient Identifier
69G8BD63PP
Background

Bortezomib is a dipeptide boronic acid derivative and proteasome inhibitor used to treat multiple myeloma and mantle cell lymphoma. The 26S proteasome is a protein complex that degrades ubiquitinated proteins in the ubiquitin-proteasome pathway: reversible inhibition of the 26S proteasome, leading to cell cycle arrest and apoptosis of cancer cells, is though...

Indication

Bortezomib is indicated for the treatment of adults with multiple myeloma or mantle cell lymphoma.

Associated Conditions
Mantle Cell Lymphoma (MCL), Multiple Myeloma (MM)
Associated Therapies
-
Clinical Trials
Related News

Daratumumab-Based Therapy for the Treatment of Newly Diagnosed Multiple Myeloma With Kidney Failure

First Posted Date
2020-04-20
Last Posted Date
2024-07-01
Lead Sponsor
Emory University
Target Recruit Count
17
Registration Number
NCT04352205
Locations
🇺🇸

Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia, United States

Rituximab, Venetoclax, and Bortezomib for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma

First Posted Date
2020-02-26
Last Posted Date
2020-06-16
Lead Sponsor
Rutgers, The State University of New Jersey
Registration Number
NCT04285268
Locations
🇺🇸

Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States

A Study of Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly-Diagnosed Multiple Myeloma

First Posted Date
2020-02-13
Last Posted Date
2024-06-14
Lead Sponsor
University of Miami
Target Recruit Count
306
Registration Number
NCT04268498
Locations
🇺🇸

University of Miami, Miami, Florida, United States

🇺🇸

MD Anderson Cancer Center, Houston, Texas, United States

🇺🇸

Moffitt Cancer Center, Tampa, Florida, United States

and more 6 locations

Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma

First Posted Date
2020-01-29
Last Posted Date
2024-10-24
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
494
Registration Number
NCT04246047
Locations
🇬🇧

GSK Investigational Site, Sutton, United Kingdom

Bortezomib, Isatuximab, Cyclophosphamide and Dexamethasone Induction in Transplant-Eligible Multiple Myeloma Patients

First Posted Date
2020-01-27
Last Posted Date
2024-01-09
Lead Sponsor
Medical College of Wisconsin
Target Recruit Count
41
Registration Number
NCT04240054
Locations
🇺🇸

Rush University Medical Center, Chicago, Illinois, United States

🇺🇸

Froedtert Hospital & the Medical College of Wisconsin, Milwaukee, Wisconsin, United States

A Study Comparing JNJ-68284528, a CAR-T Therapy Directed Against B-cell Maturation Antigen (BCMA), Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Participants With Relapsed and Lenalidomide-Refractory Multiple Myeloma

First Posted Date
2019-12-02
Last Posted Date
2024-12-06
Lead Sponsor
Janssen Research & Development, LLC
Target Recruit Count
419
Registration Number
NCT04181827
Locations
🇺🇸

University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States

🇺🇸

University of Alabama at Birmingham, Birmingham, Alabama, United States

🇺🇸

Mayo Clinic Cancer Center-Scottsdale, Phoenix, Arizona, United States

and more 85 locations

TEAM-Trial: Targeting Epigenetic Therapy Resistance in AML With Bortezomib

First Posted Date
2019-11-22
Last Posted Date
2023-03-27
Lead Sponsor
University Hospital Heidelberg
Target Recruit Count
50
Registration Number
NCT04173585
Locations
🇩🇪

University Hospital Heidelberg, Internal Medicine V, Heidelberg, Baden-Württemberg, Germany

Daratumumab Combined With Bortezomib, Cyclophosphamide and Dexamethasone for the Treatment of Multiple Myeloma Patients Presenting With Extramedullary Disease

First Posted Date
2019-11-18
Last Posted Date
2022-11-08
Lead Sponsor
Stichting European Myeloma Network
Target Recruit Count
41
Registration Number
NCT04166565
Locations
🇬🇷

Anticancer Hospital of Thessaloniki, Thessaloníki, Greece

🇮🇹

University of Bologna, Bologna, Italy

🇮🇹

Univerity of Turin, Torino, Italy

and more 5 locations

Phase 2 Study With Minimal Residual Disease (MRD) Driven Adaptive Strategy in Treatment for Newly Diagnosed Multiple Myeloma (MM) With Upfront Daratumumab-based Therapy

First Posted Date
2019-10-25
Last Posted Date
2024-10-09
Lead Sponsor
University of Michigan Rogel Cancer Center
Target Recruit Count
57
Registration Number
NCT04140162
Locations
🇺🇸

University of Michigan Rogel Cancer Center, Ann Arbor, Michigan, United States

🇺🇸

University of Texas Southwestern -- Simmons Comprehensive Cancer Center, Dallas, Texas, United States

🇺🇸

University of Rochester, Rochester, New York, United States

and more 1 locations

A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Participants With Multiple Myeloma

First Posted Date
2019-10-21
Last Posted Date
2024-12-06
Lead Sponsor
Janssen Research & Development, LLC
Target Recruit Count
237
Registration Number
NCT04133636
Locations
🇺🇸

Virginia Commonwealth University - Massey Cancer Center, Richmond, Virginia, United States

🇺🇸

University Of California San Diego, San Diego, California, United States

🇺🇸

University of California San Francisco, San Francisco, California, United States

and more 43 locations
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy